NCT02304913 Hypoglossal Acupuncture for Dysgeusia in Patients Undergoing Chemotherapy
| NCT ID | NCT02304913 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universität Duisburg-Essen |
| Condition | Acupuncture |
| Study Type | INTERVENTIONAL |
| Enrollment | 75 participants |
| Start Date | 2015-01-01 |
| Primary Completion | 2027-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 75 participants in total. It began in 2015-01-01 with a primary completion date of 2027-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This randomized controlled trial aims to investigate hypoglossal acupuncture in comparison to sham acupuncture and standard medical treatment (dietary recommendations) in the treatment of dysgeusia in cancer patients undergoing chemotherapy.
Eligibility Criteria
Inclusion Criteria: * Initial treatment with platinum-containing or taxane-based CTX (regardless of the the length of the CTX cycle) * Senological, gynecological or internistic tumors * Phantogeusia (on average ≥4 NRS) * Willingness to participate in the study and written informed consent Exclusion Criteria: * Severe stomatitis * Dysgeusia before the CTX based on neurological diseases, diabetes, or the ingestion of drugs with taste disorders as side effects * Leucopenia/neutropenia * Intake of anticoagulants * Smoking * Severe physical or mental comorbidity (due to which the patient is unable to participate in the study) * Participation in other CAM treatments within the integrative oncology care * Participation in other studies on the effectiveness of interventions for oral complications
Contact & Investigator
Gustav Dobos, Prof., MD
STUDY DIRECTOR
Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen
Frequently Asked Questions
Who can join the NCT02304913 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acupuncture. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02304913 currently recruiting?
Yes, NCT02304913 is actively recruiting participants. Contact the research team at heidemarie.haller@uk-essen.de for enrollment information.
Where is the NCT02304913 trial being conducted?
This trial is being conducted at Essen, Germany, Mannheim, Germany, Stuttgart, Germany.
Who is sponsoring the NCT02304913 clinical trial?
NCT02304913 is sponsored by Universität Duisburg-Essen. The principal investigator is Gustav Dobos, Prof., MD at Center for Integrative Medicine and Health, University Hospital Essen, University of Duisburg-Essen. The trial plans to enroll 75 participants.